Mainstreaming Ovarian Cancer Genetic Testing
developed by the Mainstreaming Working party of the
Clinical Oncology Society of Australia (COSA) Cancer Genetics Special
Interest Group. It is part
of a clinical training initiative introducing ‘mainstreaming’ of
for women with high-grade non-mucinous ovarian cancer.
‘Mainstreaming’ refers to genetic testing being offered by
non-genetics oncology health professionals, to
enable more widespread
genetic testing of women with ovarian cancer
meet current criteria.
representative of each of the invited groups (medical
nurses) will present
a review of current practice in treatment and management of high-grade serous
ovarian cancer in Western Australia.
Natalie Percival will provide first-hand
experience of the role of oncology nurses in the
BRCA testing pathway. She will discuss her experience with
mainstreaming at the Royal
Marsden Hospital in London, and how
this can be applied within oncology departments in Australia
Following completion of the in-service,
medical oncologists and gynae-oncologists will be able to directly order BRCA1/2 genetic testing through PathWest Diagnostic Genomics for women
with high grade non-mucinous ovarian cancer